TG Therapeutics Reports Q1 2026 Earnings and Raises Full-Year Revenue Guidance
TG Therapeutics (TGTX) reported Q1 2026 earnings with U.S. BRIUMVI net product revenue of $195 million, exceeding guidance. The company raised its full-year U.S. revenue guidance to $885 million to $900 million and global revenue guidance to approximately $925 million. Operating and net income also increased year-over-year.
Tickers: $TGTX
Topics: cash_balance guidance net_income operating_income revenue